Mucosal adjuvant
AssigneesDenka Company Limited, National University Corporation Kumamoto University
InventorsShogo MISUMI, Naoki KISHIMOTO, Ryotaro MITSUMATA, Nagisa NAKATA, Takuma GOTANDA
Life of this patent
Estimating the term…
Abstract
A mucosal adjuvant may have high mucosal immunogenicity and high safety and be useful in the preparation of mucosal vaccines, and a mucosal vaccine composition may include the same. Such mucosal adjuvant may include TGDK. A method for preparing the mucosal vaccine composition may include mixing TGDK with an immunogen.
Claims9
A mucosal adjuvant, comprising:
- TGDK.
A mucosal adjuvant composition, comprising:
- TGDK;
- and
- a pharmaceutically acceptable carrier.
TGDK adapted for use as a mucosal adjuvant.
A composition, comprising:
- TGDK;
- and
- an immunogen,
- wherein the composition is suitable for use in mucosal vaccine therapy.
8-9. (canceled)
A mucosal vaccine therapy, comprising:
- administering an effective amount of a composition comprising TGDK and an immunogen to a subject in need thereof.
Dependencies are inferred from the claim text.